newsfilter
← Latest News
GlobeNewswire·

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Bimatoprost-Drug Ring System (BIM-DRS)